UK markets closed

Prothena Corporation plc (PRTA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
30.41-0.96 (-3.06%)
At close: 04:00PM EDT
30.01 -0.40 (-1.32%)
After hours: 05:14PM EDT

Prothena Corporation plc

77 Sir John Rogerson’s Quay
Block C Grand Canal Docklands
Dublin 2
Ireland
353 1 236 2500
https://www.prothena.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees82

Key executives

NameTitlePayExercisedYear born
Dr. Gene G. Kinney Ph.D.Pres, CEO & Director1.02MN/A1969
Mr. Tran B. Nguyen M.B.A.CFO & Chief Strategy Officer745.35kN/A1974
Mr. Brandon S. SmithChief Operating Officer648.34kN/A1975
Ms. Carol D. KarpChief Regulatory Officer679.3kN/A1953
Dr. Hideki Garren M.D., Ph.D.Chief Medical Officer859.64kN/A1965
Ms. Karin L. Walker CPA, CPAChief Accounting Officer & ControllerN/AN/A1963
Dr. Wagner M. ZagoChief Scientific OfficerN/AN/A1973
Ms. Jennifer ZibudaDirector of Investor Relations & CommunicationN/AN/AN/A
Mr. Michael J. MalecekChief Legal OfficerN/AN/A1966
Dr. Radhika Tripuraneni M.D., M.P.H.Chief Devel. OfficerN/AN/A1980
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.

Corporate governance

Prothena Corporation plc’s ISS governance QualityScore as of 31 July 2022 is 5. The pillar scores are Audit: 8; Board: 4; Shareholder rights: 4; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.